We identified only Cys212 and Cys214, among the conserved cysteine residues in GalNAc-T1, as free cysteine residues, by cysteine-specific labeling of GalNAc-T1.. Ourresults indicate that C
Trang 1Identification of two cysteine residues involved in the binding
of UDP-GalNAc to UDP-GalNAc:polypeptide
Mari Tenno1, Shinya Toba1, Fere´nc J Ke´zdy3, A˚ke P Elhammer3and Akira Kurosaka1,2
1
Department of Biotechnology Faculty of Engineering, and2Institute for Comprehensive Research, Kyoto Sangyo University, Kamigamo-motoyama, Kyoto, Japan; 3 Pharmacia Corporation, Kalamazoo, Michigan, USA
Biosynthesis of mucin-type O-glycans is initiated by a family
of UDP-GalNAc:polypeptide
N-acetylgalactosaminyl-transferases, which contain several conserved cysteine
resi-dues among the isozymes We found that a cysteine-specific
reagent, p-chloromercuriphenylsulfonic acid (PCMPS),
irreversibly inhibited one of the isozymes (GalNAc-T1)
Presence of either UDP-GalNAc or UDP during PCMPS
treatment protected GalNAc-T1 from inactivation, to the
same extent This suggests that GalNAc-T1 contains free
cysteine residues interacting with the UDP moiety of the
sugardonor Forthe functional analysis of the cysteine
residues, several conserved cysteine residues in GalNAc-T1
were mutated individually to alanine All of the mutations
except one resulted in complete inactivation or a drastic
decrease in the activity, of the enzyme We identified only
Cys212 and Cys214, among the conserved cysteine residues
in GalNAc-T1, as free cysteine residues, by cysteine-specific
labeling of GalNAc-T1 To investigate the role of these two
cysteine residues, we generated cysteine to serine mutants (C212S and C214S) The serine mutants were more active than the corresponding alanine mutants (C212A and C214A) Kinetic analysis demonstrated that the affinity of the serine-mutants for UDP-GalNAc was decreased, as compared to the wild type enzyme The affinity for the acceptorapomucin, on the otherhand, was essentially unaffected The functional importance of the introduced serine residues was further demonstrated by the inhibition of all serine mutant enzymes with diisopropyl fluorophosphate
In addition, the serine mutants were more resistant to modification by PCMPS Ourresults indicate that Cys212 and Cys214 are sites of PCMPS modification, and that these cysteine residues are involved in the interaction with the UDP moiety of UDP-GalNAc
Keywords: cysteine; GalNAc-transferase; mucin; O-glyco-sylation; UDP-GalNAc
Mucin-type O-glycosylation is an important
post-transla-tional modification that is widely distributed on many
secretory and membrane glycoproteins [1,2] The initial step
of this glycosylation is catalyzed by the
UDP-GalNAc:poly-peptide N-acetylgalactosaminyltransferases
(GalNAc-trans-ferases; EC 2.4.1.41) These enzymes transfer GalNAc from
UDP-GalNAc to serine or threonine residues of proteins [3]
Recent progress in molecular cloning has revealed that the
GalNAc-transferases constitute a large gene family, with 10
distinct isozymes identified to date [4–14], and that they are
type II membrane proteins with a short N-terminal
cytoplasmic tail, a hydrophobic transmembrane anchor, a
luminal stem region, and a large luminal putative catalytic domain (Fig 1) The luminal putative catalytic domain contains two distinct subdomains; a central catalytic domain and a C-terminal lectin-like domain The central catalytic domain can be further subdivided into two regions The N-terminal half is represented by a glycosyltransferase 1 (GT1) motif that is conserved among a wide range of glycosyltransferases [15] The extreme C-terminal end of the GT1 motif contains a so-called DXH motif, which corres-ponds to the DXD sequence common to many glyco-syltransferases [16] The C-terminal half of the catalytic domain contains a so-called Gal/GalNAc-T motif, a sequence segment where significant homology can be seen between b1,4-galactosyltransferases and GalNAc-transfer-ases [15,17] A C-terminal lectin-like domain, called the (QXW)3 repeats, occurs exclusively in the GalNAc-trans-ferases [18,19]
Although recent reports show that the GalNAc-transfer-ases all have common structural features and the conserved motifs described above, the exact role of each domain in catalysis remains largely unknown Moreover, these enzymes are also characterized by the presence of highly conserved cysteine residues, several of which are positioned
in and around the conserved motifs (Fig 1) In order to obtain more detailed information on the structure–function relationship of the GalNAc-transferases, we investigated the possible role(s) of the conserved cysteine residues
in GalNAc-T1 We used site-directed mutagenesis, in
Correspondence to A Kurosaka, Department of Biotechnology,
Faculty of Engineering, Kyoto Sangyo University,
Kamigamo-motoyama, Kita-ku, Kyoto 603-8555, Japan.
Fax: + 81 75 705 1914, Tel.: +81 75 705 1894,
E-mail: kurosaka@cc.kyoto-su.ac.jp
Abbreviations: ABD-F, 4-(aminosulfonyl)-7-fluoro-2, 1,
3-benzoxa-diazole; DFP, diisopropyl fluorophosphate; GalNAc,
N-acetylgalac-tosamine; GalNAc-transferase, UDP-GalNAc:polypeptide
N-acetylgalactosaminyltransferase; GT1, glycosyltransferase 1; NEM,
N-ethylmaleimide; PCMPS, p-chloromercuriphenylsulfonic acid;
UBD, UDP-binding domain; TFA, trifluoroacetic acid.
Enzymes: UDP-GalNAc:polypeptide
N-acetylgalactosaminyl-transferases (GalNAc-N-acetylgalactosaminyl-transferases; EC 2.4.1.41).
(Received 16 May 2002, revised 9 July 2002, accepted 18 July 2002)
Eur J Biochem 269, 4308–4316 (2002) FEBS 2002 doi:10.1046/j.1432-1033.2002.03123.x
Trang 2combination with identification of free cysteine residues
(defined as cysteine residues not involved in the formation of
a disulfide bond), by cysteine-specific labeling, to study the
mechanistic involvement of the conserved cysteine residues
in the function of GalNAc-T1 Our results demonstrate that
Cys212 and Cys214, which are located at the C terminus of
the DXH motif, are free cysteine residues that interact with
the nucleotide moiety of UDP-GalNAc, possibly through
hydrogen bonding
E X P E R I M E N T A L P R O C E D U R E S
Preparation of soluble bovine GalNAc-T1
A soluble form of bovine GalNAc-T1 was expressed in
High Five cells using the baculovirus expression system The
molecule was purified to homogeneity by
apomucin-Sepharose chromatography as described previously [20]
Construction of soluble rat recombinant GalNAc-T1
and expression in COS7 cells
Rat GalNAc-T1 cDNA was obtained as outlined by Hagen
et al [21] Forthe construction of soluble GalNAc-T1, rat
GalNAc-T1 full-length cDNA was subcloned into pcDNA4
to create the vector, prT1 prT1 was linearized with BamHI,
and then digested with Bal31 nuclease The Bal31 digest was
blunt-ended and digested with NotI The resulting digest
was ligated into the EcoRV and NotI sites of pcDNA4,
obtaining pDN42 that encodes GalNAc-T1 with 42
N-terminal amino acid residues, including a cytoplasmic
tail and a transmembrane domain, deleted A NheI-SmaI
fragment of the plasmid pGIR201protA (a gift from H Kitagawa, Kobe Pharmaceutical University) [22,23], containing a cDNA encoding the insulin signal sequence and the Protein A-IgG binding domain, was inserted into NheI-HindIII digested pcDNA3.1, producing the vector, pInsProA pDN42 was digested with BamHI and NotI, and was subcloned into pInsProA, generating the plasmid pInsProADN42 containing truncated rat GalNAc-T1 fused with IgG-binding domain of Protein A (P-DN42)
Site-directed mutagenesis Site-directed mutagenesis was performed on pInsProADN42 using the LA PCRTM in vitro mutagenesis kit, using the primers listed Nucleotides shown in italic are nucleotides mutated to convert conserved cysteine residues into either alanine or serine residues C106a, 5¢-TAGAGGGGGCTA AAACAAAA-3¢; c212a, 5¢-ACTGTGCACTCGGCGTG AGC-3¢; c214a, 5¢-ACTGTGGCCTCGCAGTGAGC-3¢; c235a, 5¢-TAGGAGCCACCACTGTCCTC-3¢; c330a, 5¢-CAGAGTCCCTCCAGCCTGCC-3¢; c339a, 5¢-GGAG GCCGTCACTATTTCCA-3¢; c408a, 5¢-GAAAGGCTTG GCCTGTAGTT-3¢; c212s, 5¢-GCTCACAGCGAGTGCA CAGT-3¢; c214s, 5¢-GCTCACTGCGAGAGCACAGT-3¢; c212s/c214s, 5¢-GCTCACAGCGAGAGCACAGT-3¢ Expression of P-DN42 and mutant P-DN42 in COS7 cells Expression construct (pInsProADN42 ormutant pInsPro-ADN42) was transfected into COS7 cells using FuGENETM6 Transfection Reagent Three days after the transfection, the culture medium was collected and the
Fig 1 Schematic representation of the domain structure and the position of the cysteine residues in the cloned GalNAc-transferases Arrows indicate cysteine residues and the numbers indicate residues mutated in this study The amino acid residue numbering is based on the GalNAc-T1 sequence Highly conser ved cysteine r esidues ar e r epr esented by dotted lines b, r , hT1, bovine, r at, and human GalNAc-T1; hT2, human GalNAc-T2; hT3, human GalNAc-T3; hT4, human GalNAc-T4; rT5, rat GalNAc-T5; hT6, human GalNAc-T6; hT7, human GalNAc-T7; hT8, human GalNAc-T8; hT9, human GalNAc-T9; rppGaNTase-T9, rat ppGaNTase-T9.
Trang 3secreted enzyme was purified on IgG-Sepharose For
analysis by SDS/PAGE, the resins adsorbed with the
secreted enzyme were boiled in SDS/PAGE loading buffer
The resulting supernatant was loaded directly on the gel
For Western blotting, the proteins on the membrane were
visualized by incubating the blot with an affinity purified,
alkaline phosphatase-conjugated, rabbit antibody to mouse
IgG, followed by staining with nitrobluetetrazolium and
5-bromo-4-chloro-3-indolylphosphate The protein bands
on the immunoblots was quantified by densitometry
scanning and the intensity of each band was determined
using the NIH Image software The enzymatic activity of
the P-DN42 and mutant P-DN42 gene products was
determined as described below The activity levels were
corrected for enzyme protein concentration in the medium
Assay for GalNAc-transferase activity (PD-10 assay)
The enzyme activity was determined in a reaction mixture
composed of 50 mM imidazole buffer(pH 7.2), 10 mM
MnCl2, 0.1% Triton X-100, 6 nmol UDP-3H-GalNAc
(approximately 10 000 d.p.m.), 150 lg apomucin [24],
and an appropriate amount of enzyme The mixture was
incubated for30 min at 37C, and the reaction was stopped
by adding 0.25M EDTA The reaction mixture was then
separated on a PD-10 column The void fraction containing
3H-labeled apomucin was recovered and the radioactivity
was determined
Modification of GalNAc-T1 with PCMPS and DFP
Purified soluble bovine GalNAc-T1 or a recombinant
mutant rat GalNAc-T1 was treated with
p-chloromercuri-phenylsulfonic acid (PCMPS) in 40 mM imidazole buffer
(pH 7.2) for 90 min at room temperature, or with
diiso-propyl fluorophosphate (DFP) in 40 mMimidazole buffer
(pH 7.2) for 30 min at 37C Following treatment, the
reaction mixture was dialyzed against 25 mM imidazole
buffer(pH 7.2) containing 300 mM NaCl, 10% glycerol,
and 0.1% taurodeoxycholate The enzymatic activity of the
samples was determined using the PD-10 assay (see above)
To study the influence of UDP-GalNAc orUDP on the
effect of PCMPS, the treatment was carried out in 0.1 mM
PCMPS in the presence of UDP-GalNAc or UDP
Identification of free cysteine residues
Labeling of bovine GalNAc-T1 with ABD-F and
fraction-ation of the labeled peptides were carried out as described
[25,26] Briefly, GalNAc-T1 was first labeled with ABD-F,
followed by reduction with tributylphosphine and
S-carbo-xymethylation with iodoacetic acid The alkylated protein
was digested with endoproteinase Lys-C The digest was
then fractionated by HPLC on a C18HPLC column The
fluorescent peptides were purified by rechromatography on
a C8 column and sequenced with an automated Edman
sequencer
Kinetic analysis
Km forUDP-GalNAc was obtained by varying the
concentration of UDP-GalNAc from 1.5 to 43.5 lM in
the presence of 1.88 mgÆmL)1apomucin To determine the
Kmfor apomucin, GalNAc-transferase activity was assayed
in the presence of 7.5 lM UDP-GalNAc and 0.625–8.75 mgÆmL)1 apomucin Calculation of kinetic parameters was done from double reciprocal plots (1/v vs 1/[S]), using standard procedures
R E S U L T S
Involvement of the free cysteine residues of GalNAc-T1
in catalysis
To investigate the functional role of the cysteine residues (Fig 1), we first modified GalNAc-T1 with a cysteine-specific reagent, PCMPS We then examined the influence
of the modification on the GalNAc-transferase activity A purified bovine GalNAc-T1, expressed as a secreted protein
in High Five cells, was used forthis experiment [20] As shown in Fig 2, PCMPS caused a marked, concentration dependent decrease in enzyme activity, with a Ki of 0.03 mM This suggests that free cysteine residues, possibly located at the catalytic site of GalNAc-T1, might be involved in the catalytic function of the enzyme
To investigate whetherthe cysteine residues modified by PCMPS are involved in the binding of UDP-GalNAc,
we treated recombinant GalNAc-T1 with PCMPS in the presence of either UDP-GalNAc or UDP To increase the sensitivity in this experiment, the cysteine modification was performed with the minimal PCMPS concentration (0.1 mM) required for complete inhibition of GalNAc-T1 (Fig 2) Fig 3 shows that GalNAc-T1 retained enzymatic activity in the presence of either UDP or UDP-GalNAc This suggests that the sulfhydryl groups of free cysteine residues modified by PCMPS may interact with UDP-GalNAc, orat least be located in the UDP-GalNAc binding cleft Furthermore, the data suggest that the cysteine residues predominantly interact with a UDP moiety of UDP-GalNAc, as UDP and UDP-GalNAc were equally effective at protecting the enzyme from inactivation
Fig 2 Inhibition of GalNAc-T1 with PCMPS Purified bovine GalNAc-T1 was incubated with increasing concentrations of PCMPS for 90 min at room temperature Following incubation, the treated enzyme was dialyzed to remove excess PCMPS, and assayed for activity as described in Experimental procedures.
Trang 4Mutagenesis of the cysteine residues in and around
the GT1 and Gal/GalNAc-T motifs
To investigate which cysteine residues are involved in the
catalytic function of GalNAc-T1, site-directed mutagenesis
was carried out on the conserved cysteine residues in the
catalytic domain A rat GalNAc-T1 cDNA, cloned by PCR
as outlined by Hagen et al [21], was used forthis
experiment Rat GalNAc-T1 is 98% identical to the bovine
ortholog and all of the cysteine residues are conserved
between the two enzymes (Fig 1) Forease of purification
and detection, 42 N-terminal amino acid residues containing
the cytoplasmic tail and the transmembrane region were
deleted from the rat isozyme, and an insulin signal sequence
and a Protein A-IgG binding domain were fused to the
resulting N terminus of the sequence The recombinant
truncated GalNAc-T1 was then expressed in COS7 cells and
the secreted fusion protein was purified from the culture
medium on IgG-Sepharose The purified recombinant,
truncated rat GalNAc-T1, designated P-DN42, retained full
enzymatic activity and had kinetic properties almost
identi-cal to those of soluble bovine GalNAc-T1 [27] Hence, it was
used forthe following site-directed mutagenesis studies The
amount of fusion protein secreted into the medium was
quantified by Western blotting in combination with
densi-tometric scanning of the bands on the blotting membrane
The enzymatic activities were correlated with the
concen-tration of recombinant proteins in the media This was done
to evaluate the effects of the mutations on both the specific
activity and the absolute levels of the secreted mutant
enzymes In a first experiment, we mutated Cys106, Cys212,
Cys214, and Cys235 in P-DN42, individually, to alanine
These residues are located in (Cys212 and Cys214), and
around (Cys106 and Cys235) the GT1 motif Mutation of
C106A, C212A, and C214A, resulted in a considerable
decrease in secretion of the mutant proteins (Fig 4),
indicating that the replacement of cysteine with alanine
significantly affected enzyme stability and/orefficiency of
secretion Apomucin was used as the acceptor when
comparing the activity of the secreted mutants As shown
in Fig 4, C106A was completely inactive The relative activities of C212A and C214A were drastically decreased,
to 6% and 17% of that of P-DN42, respectively These results indicate that the conserved Cys106, Cys212, and Cys214 residues are essential for efficient enzyme function
In contrast, the C235A mutant retained almost full activity,
as well as a high level of secretion into the culture medium Hence, Cys235 appears not to be required for GalNAc-T1 activity orsecretion
The Gal/GalNAc-T motif contains one conserved cysteine residue, Cys330 In addition, there are two conserved cysteine residues (Cys339 and Cys408) at the C-terminal side of this motif Each of these cysteine residues was also mutated to alanine Secretion of the mutants, especially C339A, decreased significantly Moreover, there was a complete loss of activity in all three mutant enzymes (Fig 4) These results demonstrate that the cysteine residues
in positions 330, 339 and 408 are important for both secretion and function of GalNAc-T1
Identification of free cysteine residues in GalNAc-T1 The inactivation observed for several of the GalNAc-T1 mutants may result either from conformational changes caused by the disruption of disulfide bridges or from mutational effects of cysteine residues involved in enzyme function However, the results from modification of GalNAc-T1 with PCMPS (Fig 2) strongly suggest the presence of essential, free cysteine residues To identify the free cysteine residues in the native enzyme, we labeled soluble bovine GalNAc-T1 with a cysteine specific
Fig 3 Protection of T1 from PCMPS inactivation
GalNAc-T1 was tr eated with 0.1 m M PCMPS in the presence of increasing
concentrations of UDP-GalNAc (d) and UDP (s) Following
incu-bation, the enzyme activity was determined as described in Fig 2.
Fig 4 Enzyme activity of GalNAc-T1 with mutated cysteine residues Each mutant was expressed in COS7 cells and the secreted recom-binant protein was recovered from the culture medium The amount of the secreted protein was determined by Western blotting followed by the densitometric scanning (lower panel) The enzymatic activity secreted in the medium was corrected for the amount of mutant proteins in the medium and expressed as activity relative to that of the wild-type, P-DN42 Solid bars represent percent enzyme activity relative to that of P-DN42 (hatched bars).
Trang 5fluorescent reagent, 4-(aminosulfonyl)-7-fluoro-2, 1,
3-ben-zoxadiazole (ABD-F), in the absence of reducing agent
[25,26] ABD-F is nonfluorescent until it reacts with thiols
Therefore, free cysteine residues can be identified as carrying
a fluorescent label following ABD-F treatment of a protein
Purified bovine GalNAc-T1 was first labeled with ABD-F,
followed by reduction and S-carboxymethylation The
labeled, reduced enzyme was then cleaved with
endopro-teinase Lys-C, and the resulting peptide fragments were
fractionated by HPLC on a C18column As shown in Fig 5,
a number of peptide peaks absorbing at 220 nm, were
detected but only a few were fluorescent All of the major
fluorescent peaks (indicated by arrows) were collected and
re-fractionated by HPLC using a C8column This revealed
that peaks 1, 2, and 3 were artifacts as all of them separated
into several small peaks on the C8column and none of these
(secondary peaks) contained any polypeptide sequence
detectable by sequence analysis (data not shown) By
contrast, peak 4 produced a single peak on the C8column
Edman analysis showed that this peak contained an ABD-F
labeled peptide The peptide contained the N-terminal
sequence G202QVITFLDAHC212EC214TV The sequence
includes the GalNAc-T1 DXH motif (underlined above), a
region believed to be involved in coordination of a divalent
cation orthe binding of UDP-GalNAc [16,28,29] The two
cysteine residues in the sequence, Cys212 and Cys214, were
both labeled by ABD-F (Fig 6), as demonstrated by the
presence of a peak corresponding to fluorescent cysteine and
the complete absence of a peak corresponding to
carbo-xymethylated cysteine, in the sequence analysis of the
peptide Consequently, both Cys212 and Cys214 can be
considered free cysteine residues that probably are exposed
on the surface of the UDP-binding pocket The other
essential cysteine residues, which were identified by
muta-tional analysis but not labeled by ABD-F, may form
intramolecular disulfide bonds required for proper folding
of the enzyme Cys235, on the otherhand, does not seem to
be involved in formation of a disulfide bond, as mutation at this site did not affect the activity of the enzyme (Fig 4) Why this residue was not labeled with ABD-F is not clear
Fig 5 HPLC fractionation of endoproteinase Lys-C digest of ABD-F labeled GalNAc-T1 Soluble bovine GalNAc-T1 was labeled with ABD-F, reduced with tributylphosphine, alkylated with iodoacetic acid, and then digested with endoproteinase Lys-C The digest was loaded onto a C 18 column (4.6 · 250 mm) equilibrated with 0.1% trifluoroacetic acid Elution was carried out with a linear gradient from 0 to 50% acetonitrile in 0.1% trifluoroacetic acid, at flow rate of 1 mLÆmin)1 The chromatograms were monitored by (A) relative absorbance at
220 nm and (B) by relative fluorescence (excitation at 385 nm, emission at 520 nm) The peaks labeled 1–4 were pooled and re-fractionated by C 8 column chromatogra-phy forsubsequent amino acid sequence analysis.
Fig 6 Amino acid sequence analysis of the ABD-F labeled peptide The amino acid sequence of the fluorescent peptide (peak 4 in Fig 5) was determined with an automated Edman sequencer The solid and the open arrows indicate the elution position of ABD-F labeled cysteine, and S-carboxymethylated cysteine, respectively HPLC profiles of (A) cycle 11 (Cys212) and (B) 13 (Cys214) ar e shown.
Trang 6As the fluorescent labeling was performed without
dena-turing reagents, it is possible that only free cysteine residues
exposed to the solvent were labeled by the ABD-F
Expression and kinetic studies of cysteine-to-serine
mutant GalNAc-T1 enzymes
The findings that the activities of the C212A and C214A
mutants were drastically decreased and that UDP or
UDP-GalNAc prevented PCMPS inactivation of UDP-GalNAc-T1
suggest that electrostatic interactions through the polar
sulfhydryl groups of these cysteine residues may be
involved in the interaction(s) between the nucleotide moiety
of UDP-GalNAc and GalNAc-T1 To examine this
hypothesis, we generated two single point mutants,
C212S and C214S, and one double point mutant, C212S/
C214S In these mutants, the cysteine residues (212 and
214) were replaced by serine residues, thereby generating
proteins with hydroxyl, instead of sulfhydryl, side chains at
positions 212 and 214 This should allow retained
hydro-gen bonding capacity at these positions and at least
theoretically, if this capacity is an essential function of these
residues, result in functional enzyme The results shown in
Fig 7 suggest that this is indeed the case C212S and
C214S retained approximately 60% and 80% of parent
enzyme activity, respectively This is significantly higher
than the activity of the corresponding alanine mutants (6%
and 17%, respectively) (Fig 4) The activity of the double
mutant, C212S/C214S, was lowerbut still amounted to
40% of the parent enzyme activity
In a more in-depth evaluation of the function of the three
serine mutants, the kinetic properties of the mutant enzymes
were compared to those of the parent enzyme, P-DN42 As
shown in Table 1, the Kmvalues of all three mutants, for
apomucin, were essentially the same as that of P-DN42,
indicating that Cys212 and Cys214 are not involved in
the recognition of the acceptor By contrast, the affinity of
the mutant enzymes forUDP-GalNAc was affected quite
significantly When serine was substituted for Cys214, the
increase in Kmwas only slight ( 1.2-fold that of P-DN42)
On the otherhand, C212S showed a 3.4-fold increase in Km Furthermore, the effect of mutating the two cysteine residues appear to be cooperative as the double mutant, C212S/C214S, shows an even higherincrease in Km(5-fold) These results demonstrate that while Cys212 may be a majorsite of interaction with UDP-GalNAc, Cys214 is also involved in binding
PCMPS and DFP modification of the serine-mutants
of GalNAc-T1
We also examined the sensitivity of the three serine mutants
to PCMPS inactivation (shown in Fig 8) C214S, which contains free Cys212, was inactivated by PCMPS with a Ki
of 0.03 mMalmost identical to that of native GalNAc-T1
On the other hand, C212S was more resistant to the treatment The Ki of 0.65 mM, may be due to a lower reactivity of Cys214 as compared to Cys212 Moreover, no inhibition was observed for C212S/C214S, even in the presence of a large excess of PCMPS (1 mM), that resulted
in the complete inactivation of P-DN42 These results show that both Cys212 and Cys214 are modified by PCMPS, and that, consistent with the kinetic data, Cys212 is the most
Fig 7 Enzymatic activity of cysteine-to-serine mutant GalNAc-T1
enzymes Enzyme activity measurements and Western blotting of
mutant proteins were carried out as described in Fig 4.
Table 1 Comparison of donor and acceptor K m values (apparent) for the parent and mutant enzymes Values shown are means of three separate determinations.
UDP-GalNAc Apomucin
K m (l M ) -fold K m (mgÆmL)1) -fold P-DN42 5.1 ± 0.8 1.0 4.7 ± 0.1 1.0 C212S 17.4 ± 3.3 3.4 4.6 ± 0.9 1.0 C214S 6.0 ± 1.1 1.2 4.0 ± 0.3 0.9 C212S/C214S 25.0 ± 3.7 5.0 4.0 ± 0.4 0.9
Fig 8 Inhibition of cysteine-to-serine mutant GalNAc-T1 enzymes with PCMPS Mutant enzymes expressed in COS7 cells were purified on IgG-Sepharose from the conditioned medium Proteins adsorbed by the resins were treated with increasing concentrations of PCMPS Following treatment the resins were washed with buffer and the enzymatic activity of the mutant proteins were determined as described
in Experimental procedures d, C212S; s, C214S; m, C212S/C214S.
Trang 7important site for the interaction with UDP-GalNAc.
Complete loss of PCMPS inactivation in the double mutant
suggests that ther e ar e no PCMPS r eactive sites in native
GalNAc-T1, otherthan Cys212 and Cys214, and that
ABD-F and PCMPS modify the same cysteine residues in
GalNAc-T1
We also investigated the function of the serine residues
introduced at positions 212 and 214 by modifying the
mutant proteins with DFP, a reagent specific for active
serine residues Native bovine GalNAc-T1 is totally
insen-sitive to DFP treatment, and thus appears not to contain
any serine residues important for enzyme function By
contrast, all three serine mutants were inactivated by DFP
to some extent (Fig 9) The inhibition was more efficient for
C212S than C214S, again demonstrating that position 212 is
the more important site for substrate interaction The
double mutant, C212S/C214S, was most susceptible to
DFP, confirming the cooperative involvement of the two
sites observed in the kinetic analysis (Table 1)
Taken together, the results from the kinetic, mutational
and chemical modification studies presented in this report
strongly suggests that the sulfhydryl groups at Cys212 and
Cys214, but primarily at Cys212, are involved in substrate
binding, possibly as hydrogen bond partners with UDP
D I S C U S S I O N
The primary aim of this study is to evaluate the functional
role(s) of the conserved cysteine residues found in the
GalNAc-transferase family Using site-directed
mutagene-sis, in combination with identification of free cysteine
residues by cysteine-specific labeling, we demonstrated that
Cys212 and Cys214, but predominantly Cys212, is involved
in the binding of the nucleotide portion of UDP-GalNAc,
most probably through hydrogen bonding This is
consis-tent with ourprevious inhibition study on GalNAc-T1
using various nucleotides and nucleotide sugars [30],
showing that the enzyme primarily recognizes the UDP
portion of the sugar donor Recent crystallographic studies
on glycosyltransferases indicate that several interactions are involved in binding of the UDP portion of the sugar donors
to the enzymes [31–37] In GalNAc-T1, hydrogen bonding with Cys212 and Cys214 appears to be predominant interactions with UDP Other interactions may contribute
in a more modest fashion, as replacement of Cys212 or Cys214 with alanine resulted in a substantial decrease, but not in a complete loss, of the activity (Fig 4) We also found that the C212S mutant enzyme works relatively efficiently, with a 3.4-fold difference in the Kmvalue forUDP-GalNAc,
as compared to P-DN42, while the activity of the corres-ponding alanine mutant, C212A, was too low fordeter -mination of kinetic parameters This relatively modest difference in efficiency between the wild-type enzyme and the C212S mutant could be a matterof the size of the hydrogen bond forming group: a hydroxyl group (–OH) is smaller than a sulfhydryl group (–SH) If hydrogen bonding
is involved in the interaction with the nucleotide sugar, substituting -OH for-SH may increase bond length slightly, thereby making it less efficient and decreasing the affinity Although we show that the interaction of Cys212 and Cys214 with the sugardonoris important forthe GalNAc-T1 activity, it should be noted that some GalNAc-transfer-ases do not have cysteine residues at the corresponding positions As shown in Fig 1, GalNAc-T1, -T2, -T3, -T4, and -T6 all contain both cysteine residues, but other GalNAc-transferases contain different amino acids at these positions, such as DSHVEC (GalNAc-T5), DAHCEV (GalNAc-T7), DAHIEV (GalNAc-T8), DAHVEF (GalNAc-T9), and DSHCEA (ppGaNTase-T9) Of these isozymes with variation at the two cysteine sites, GalNAc-T5, -T7 and ppGaNTase-T9 are catalytically active This indicates that the two cysteine residues C-terminal to the DXH motif may not be crucial for the basic catalytic function of the GalNAc-transferases, but rather are important in defining the catalytic properties of specific isozymes In fact, the interaction of UDP-GalNAc with GalNAc-T5, which has a valine residue at the Cys212 site, is less efficient than with GalNAc-T1 GalNAc-T5 has a significantly loweraffinity forUDP-GalNAc (Km¼ 55 lM) [9], than P-DN42 and its serine-mutants (Table 1) The low affinity of UDP-GalNAc forGalNAc-T5 may, at least in part, be ascribed to the substitution with valine at the Cys212 site The two isozymes GalNAc-T8 and GalNAc-T9 lack cysteine residues at both position 212 and 214 Consequently they may also have a low affinity for UDP-GalNAc and consistent with this, no enzymatic activity has so farbeen reported forthese molecules It is possible that the activity of these isozymes cannot be measured under the standard assay conditions used for other GalNAc-transferases Similarly, the importance of fourhistidine residues forGalNAc-T1 activity has been demonstrated by Wragg et al [17], using site-directed mutagenesis Of these residues, His211 and His341 are conserved in all isozymes cloned to date Some GalNAc-transferases, however, do not contain the other two histidine residues, His125 and His341 His125 and His341 are found
in six and eight isozymes out of 10, respectively Aspartic acid at the DXH motif in GalNAc-T1 is reported to be essential forGalNAc-T1 activity, because the mutation at this site results in inactivation of the enzyme [15] Contrary
to this observation, GalNAc-T4 does not contain the DXH
Fig 9 Inactivation of cysteine-to-serine mutant GalNAc-T1 enzymes
with DFP DFP treatment of mutant proteins was performed as
described in Fig 8 No change in pH was observed during the reaction.
This indicates that the inactivation of the mutants was not due to
acidification of the incubation but to modification of the active serine
residues d, C212S; s, C214S; m, C212S/C214S.
Trang 8sequence, but contains YXH instead [7] All these findings
indicate that essential amino acid residues for some
isozymes are not necessarily conserved in other isozymes
The variations in the primary sequence found in different
members of the GalNAc-transferase family could provide
each isozyme with distinct kinetic properties, thereby
enabling the specific reaction catalyzed by these enzymes
in vivo Sequence variation is also found in the
fucosyltransferases a1,3/4-Fucosyltransferases III, V, and
VI are inhibited by the cysteine specific reagent,
N-ethyl-maleimide (NEM) The presence of a free cysteine residue
has been reported for the NEM sensitive enzymes, whereas
those that are insensitive to NEM contain a serine
(a1,3/4-fucosyltransferase IV) or a threonine
(a1,3/4-fucosyltrans-ferase VII) residue at the corresponding site Importantly,
the NEM-sensitive cysteine residue is reported to be located
in ornearthe binding site forGDP-Fuc [38–41], in analogy
to what was found forGalNAc-T1
The known glycosyltransferases have been classified into
52 different families, based both on sequence similarity and
substrate/product stereochemistry (inverting or retaining),
at the carbohydrate-active enzymes server on world
wide web, URL: http://afmb.cnrs-mrs.fr/pedro/CAZY/
db.html [42,43] The crystal structures of several
glyco-syltransferases belonging to different groups have been
determined recently [31–37] Although these proteins have
no sequence identity or related functional features, the
crystallographic studies show that some of them share a
domain structure, called a UBD (UDP-binding domain)
[44], also known as a SGC (SpsA
N-acetylglucosaminyl-transferase I core) domain [28,32] The UBD is predicted to
consist of alternating a-helices and b-sheets, constituting an
a-b-a sandwich [31,44] The UBD of glycosyltransferases
also contains a DXD motif In all crystallized enzymes, the
DXD motifs are located at positions closely related to one
another and ar e expected to be in dir ect contact with the
sugar donor or interact with UDP-sugars through binding
with a divalent ion [28,29] The two cysteine residues at
positions 212 and 214 in GalNAc-T1, identified in this study
as being involved in sugardonorbinding, are in the GT1
motif A DXH motif that precedes Cys212 and Cys214 is
located at the C-terminal end of the GT1 motif The
hydrophobic cluster analysis of several glycosyltransferases
demonstrates that the DXH motif corresponds to the DXD
motif found in most other glycosyltransferases [29]
More-over, it has been reported that the GT1 motif forms a
five-stranded parallel b-sheet flanked by four a-helices and
that the amino acids essential forenzymatic activity as well
as the DXH motif are located near the C-terminal ends of
the putative b-strands, lining the face of the predicted active
site cleft [15] These proposed structural features of the GT1
motif in GalNAc-T1 are similar to the UBD, raising the
possibility that catalytic mechanisms similarto those
described above are conserved in the GalNAc-transferases
as well It therefore appears likely that Cys212 and Cys214
at the C-terminal end of the DXH motif in GalNAc-T1 are
located at the active site of the enzyme, and interact with
UDP-GalNAc through hydrogen bonding
The results presented in this report offer new insights into
the catalytic mechanism of GalNAc-T1 Identification of
amino acid residues essential for activity will help us to
understand the functions of the different domains in
GalNAc-transferases and will allow the development of
strategies for engineering new GalNAc-transferases with altered ormodified donorand/oracceptorspecificities Together with information on the three-dimensional struc-ture of the GalNAc-transferases, this will allow an under-standing of the catalytic mechanism(s) of these enzymes that
in turn can be used for development of isozyme-specific inhibitors and thereby for investigations of the functional roles of mucin carbohydrates
A C K N O W L E D G E M E N T S This work was supported in part by the Research Foundation for Pharmaceutical Science, Sasakawa Scientific Research Grant, and the Foundation for Bio-venture Research Center from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.
R E F E R E N C E S
1 Paulson, J.C & Colley, K.J (1989) Glycosyltransferases Struc-ture, localization, and control of cell type-specific glycosylation.
J Biol Chem 264, 17615–17618.
2 Jentoft, N (1990) Why are proteins O-glycosylated? Trends Biochem Sci 15, 291–294.
3 Clausen, H & Bennett, E.P (1996) A family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases control the initiation of mucin-type O-linked glycosylation Glycobioogy.
6, 635–646.
4 Homa, F.L., Hollander, T., Lehman, D.J., Thomsen, D.R & Elhammer, A˚.P (1993) Isolation and expression of a cDNA clone encoding a bovine UDP-GalNAc:polypeptide N-acetylgalactos-aminyltransferase J Biol Chem 268, 12609–12616.
5 White, T., Bennett, E.P., Takio, K., Sorensen, T., Bonding, N & Clausen, H (1995) Purification and cDNA cloning of a human UDP-N-acetyl-a-D-galactosamine: polypeptide N-acetylgalactos-aminyltransferase J Biol Chem 270, 24156–24165.
6 Bennett, E.P., Hassan, H & Clausen, H (1996) cDNA cloning and expression of a novel human UDP-N-acetyl-a- D -galactos-amine: polypeptide N-acetylgalactosaminyltransferase, GalNAc-T3 J Biol Chem 271, 17006–17012.
7 Hagen, F.K., TenHagen, K.G., Beres, T.M., Balys, M.M., VanWuyckhuyse, B.C & Tabak, L.A (1997) cDNA cloning and expression of a novel UDP-N-acetyl- D -galactosamine: polypeptide N-acetylgalactosaminyltransferase J Biol Chem 272, 13843– 13848.
8 Bennett, E.P., Hassan, H., Mandel, U., Mirgorodskaya, E., Roepstorff, P., Burchell, J., TaylorPapadimitriou, J., Hollingsworth, M.A., Merkx, G., vanKessel, A.G., Eiberg, H., Steffensen, R & Clausen, H (1998) Cloning of a human UDP-N-acetyl-a- D -galactosamine: polypeptide N-acetylgalactosaminyl-transferase that complements other GalNAc-N-acetylgalactosaminyl-transferases in complete O-glycosylation of the MUC1 tandem repeat J Biol Chem 273, 30472–30481.
9 Ten Hagen, K.G., Hagen, F.K., Balys, M.M., Beres, T.M., Van Wuyckhuyse, B & Tabak, L.A (1998) Cloning and expres-sion of a novel, tissue specifically expressed member of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family.
J Biol Chem 273, 27749–27754.
10 Bennett, E.P., Hassan, H., Mandel, U., Hollingsworth, M.A., Akisawa, N., Ikematsu, Y., Merkx, G., vanKessel, A.G., Olofsson, S & Clausen, H (1999) Cloning and characterization of
a close homologue of human UDP-N-acetyl-a- D -galactosamine: polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6 – Evidence forgenetic but not functional redundancy.
J Biol Chem 274, 25362–25370.
11 Bennett, E.P., Hassan, H., Hollingsworth, M.A & Clausen, H (1999) A novel human UDP-N-acetyl- D -galactosamine:
Trang 9polypep-tide N-acetylgalactosaminyltransferase, GalNAc-T7, with
specifi-city forpartial GalNAc-glycosylated acceptorsubstrates FEBS
Lett 460, 226–230.
12 White, K.E., Lorenz, B., Evans, W.E., Meitinger, T., Strom, T.M.
& Econs, M.J (2000) Molecularcloning of a novel human
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase,
GalNAc-T8, and analysis as a candidate autosomal dominant
hypophosphatemic rickets (ADHR) gene Gene 246, 347–356.
13 Toba, S., Tenno, M., Konishi, M., Mikami, T., Itoh, N &
Kurosaka, A (2000) Brain-specific expression of a novel human
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase
(GalNAc-T9) Biochim Biophys Acta 1493, 264–268.
14 Hagen, K.G., Bedi, G.S., Tetaert, D., Kingsley, P.D., Hagen,
F.K., Balys, M.M., Beres, T.M., Degand, P & Tabak, L.A (2001)
Cloning and characterization of a ninth member of the
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family,
ppGaNTase-T9 J Biol Chem 276, 17395–17404.
15 Hagen, F.K., Hazes, B., Raffo, R., de Sa, D & Tabak, L.A (1999)
Structure-function analysis of the UDP-N-acetyl- D
-galactosa-mine: polypeptide N-acetylgalactosaminyltransferase Essential
residues lie in a predicted active site cleft resembling a lactose
repressor fold J Biol Chem 274, 6797–6803.
16 Wiggins, C.A & Munro, S (1998) Activity of the yeast MNN1
a1,3-mannosyltransferase requires a motif conserved in many
other families of glycosyltransferases Proc Natl Acad Sci USA
95, 7945–7950.
17 Wragg, S., Hagen, F.K & Tabak, L.A (1997) Identification of
essential histidine residues in UDP-N-acetyl- D -galactosamine:
polypeptide N-acetylgalactosaminyltransferase-T1 Biochem J.
328, 193–197.
18 Hazes, B (1996) The (QxW) 3 domain: a flexible lectin scaffold.
Protein Sci 5, 1490–1501.
19 Hassan, H., Reis, C.A., Bennett, E.P., Mirgorodskaya, E.,
Roepstorff, P., Hollingsworth, M.A., Burchell, J.,
Taylor-Papadimitriou, J & Clausen, H (2000) The lectin domain of
UDP-N-acetyl- D -galactosamine: polypeptide
N-acetylgalacto-saminyltransferase-T4 directs its glycopeptide specificities J Biol.
Chem 275, 38197–38205.
20 Homa, F.L., Baker, C.A., Thomsen, D.R & Elhammer, A˚.P.
(1995) Conversion of a bovine UDP-GalNAc:polypeptide,
N-acetylgalactosaminyltransferase to a soluble, secreted enzyme,
and expression in Sf9 cells Protein Expr Purif 6, 141–148.
21 Hagen, F.K., Gregoire, C.A & Tabak, L.A (1995) Cloning and
sequence homology of a rat UDP-GalNAc:polypeptide
N-acetyl-galactosaminyltransferase Glycoconj J 12, 901–909.
22 Livingston, B.D & Paulson, J.C (1993) Polymerase chain
reac-tion cloning of a developmentally regulated member of the
sialyltransferase gene family J Biol Chem 268, 11504–11507.
23 Kitagawa, H & Paulson, J.C (1993) Cloning and expression
of human Galb1,3 (4) GlcNAc a2,3-sialyltransferase Biochem.
Biophys Res Commun 194, 375–382.
24 Hagopian, A & Eylar, E.H (1968) Glycoprotein biosynthesis:
studies on the receptor specificity of the polypeptidyl:
N-acetyl-galactosaminyltransferase from bovine submaxillary glands Arch.
Biochem Biophys 128, 422–433.
25 Toyo’oka, T & Imai, K (1985) Isolation and characterization of
cysteine-containing regions of proteins using
4-(aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole and high-performance liquid
chro-matography Anal Chem 57, 1931–1937.
26 Kirley, T.L (1989) Determination of three disulfide bonds and one
free sulfhydryl in the b subunit of (Na,K)-ATPase J Biol Chem.
264, 7185–7192.
27 Elhammer, A & Kornfeld, S (1986) Purification and
character-ization of UDP-N-acetylgalactosamine: polypeptide
N-acetyl-galactosaminyltransferase from bovine colostrum and murine
lymphoma BW5147 cells J Biol Chem 261, 5249–5255.
28 Unligil, U.M & Rini, J.M (2000) Glycosyltransferase structure and mechanism Curr Opin Struct Biol 10, 510–517.
29 Breton, C & Imberty, A (1999) Structure/function studies of glycosyltransferases Curr Opin Struct Biol 9, 563–571.
30 Elhammer, A˚.P., Ke´zdy, F.J & Kurosaka, A (1999) The acceptor specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferases Glycoconj J 16, 171–180.
31 Vrielink, A., Ruger, W., Driessen, H.P & Freemont, P.S (1994) Crystal structure of the DNA modifying enzyme b-glucosyl-transferase in the presence and absence of the substrate uridine diphosphoglucose EMBO J 13, 3413–3422.
32 Unligil, U.M., Zhou, S., Yuwaraj, S., Sarkar, M., Schachter, H & Rini, J.M (2000) X-ray crystal structure of rabbit N-acetyl-glucosaminyltransferase I: catalytic mechanism and a new protein superfamily EMBO J 19, 5269–5280.
33 Gastinel, L.N., Cambillau, C & Bourne, Y (1999) Crystal structures of the bovine b4galactosyltransferase catalytic domain and its complex with uridine diphosphogalactose EMBO J 18, 3546–3557.
34 Charnock, S.J & Davies, G.J (1999) Structure of the nucleotide-diphospho-sugar transferase, SpsA from Bacillus subtilis, in native and nucleotide-complexed forms Biochemistry 38, 6380–6385.
35 Ha, S., Walker, D., Shi, Y & Walker, S (2000) The 1.9 A˚ crystal structure of Escherichia coli MurG, a membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis Protein Sci 9, 1045–1052.
36 Pedersen, L.C., Tsuchida, K., Kitagawa, H., Sugahara, K., Darden, T.A & Negishi, M (2000) Heparan/chondroitin sulfate biosynthesis Structure and mechanism of human glucuronyl-transferase I J Biol Chem 275, 34580–34585.
37 Persson, K., Ly, H.D., Dieckelmann, M., Wakarchuk, W.W., Withers, S.G & Strynadka, N.C (2001) Crystal structure of the retaining galactosyltransferase LgtC from Neisseria meningitidis in complex with donorand acceptorsugaranalogs Nature Struct Biol 8, 166–175.
38 Holmes, E.H., Xu, Z.L., Sherwood, A & Macher, B.A (1995) Structure-function analysis of human a1,3fucosyltrnsferases.
J Biol Chem 270, 8145–8151.
39 Lowe, J.B., Kukowska-Latallo, J.F., Nair, R.P., Larsen, R.D., Marks, R.M., Macher, B.A., Kelly, R.J & Ernst, L.K (1991) Molecular cloning of a human fucosyltransferase gene that determines expression of the Lewis X and VIM-2 epitopes but not ELAM-1-dependent cell adhesion J Biol Chem 266, 17467– 17477.
40 Natsuka, S., Gersten, K.M., Zenita, K., Kannagi, R & Lowe, J.B (1994) Molecularcloning of a cDNA encoding a novel human leukocyte a1,3-fucosyltransferase capable of synthesizing the sialyl Lewis X determinant J Biol Chem 269, 16789–16794.
41 Sasaki, K., Kurata, K., Funayama, K., Nagata, M., Watanabe, E., Ohta, S., Hanai, N & Nishi, T (1994) Expression cloning of a novel a1,3-fucosyltransferase that is involved in biosynthesis of the sialyl Lewis X carbohydrate determinants in leukocytes J Biol Chem 269, 14730–14737.
42 Campbell, J.A., Davies, G.J., Bulone, V & Henrissat, B (1997) A classification of nucleotide-diphospho-sugar glycosyltransferases based on amino acid sequence similarities Biochem J 326, 929– 939.
43 Campbell, J.A., Davies, G.J., Bulone, V & Henrissat, B (1998) A classification of nucleotide-diphospho-sugar glycosyltransferases based on amino acid sequence similarities Biochem J 329, 719– 719.
44 Gastinel, L.N., Bignon, C., Misra, A.K., Hindsgaul, O., Shaper, J.H & Joziasse, D.H (2001) Bovine a1,3-galactosyltransferase catalytic domain structure and its relationship with ABO histo-blood group and glycosphingolipid glycosyltransferases EMBO J.
20, 638–649.